CN106474162A - Application in preparation prevention or treatment depression preparation for the Bacillus coagulans - Google Patents
Application in preparation prevention or treatment depression preparation for the Bacillus coagulans Download PDFInfo
- Publication number
- CN106474162A CN106474162A CN201611060368.2A CN201611060368A CN106474162A CN 106474162 A CN106474162 A CN 106474162A CN 201611060368 A CN201611060368 A CN 201611060368A CN 106474162 A CN106474162 A CN 106474162A
- Authority
- CN
- China
- Prior art keywords
- bacillus coagulans
- cfu
- preparation
- bacillus
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000193749 Bacillus coagulans Species 0.000 title claims abstract description 86
- 229940054340 bacillus coagulans Drugs 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 52
- 230000002265 prevention Effects 0.000 title claims abstract description 12
- 206010054089 Depressive symptom Diseases 0.000 claims abstract description 5
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 8
- UELITFHSCLAHKR-UHFFFAOYSA-N acibenzolar-S-methyl Chemical compound CSC(=O)C1=CC=CC2=C1SN=N2 UELITFHSCLAHKR-UHFFFAOYSA-N 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 24
- 241000700159 Rattus Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 17
- 230000037396 body weight Effects 0.000 description 13
- 230000001684 chronic effect Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 230000035882 stress Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical group C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000193755 Bacillus cereus Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000007357 depressive behavior Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- -1 body preparation Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000012048 forced swim test Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses application in preparation prevention or treatment depression preparation for the Bacillus coagulans, specifically with Bacillus coagulans prevention or treatment depression, reduce depressive symptom.
Description
Technical field
The present invention relates to application in preparation prevention or treatment depression preparation for the Bacillus coagulans, specifically with condensing
Bacillus cereuss prevention or treatment depression, reduce depressive symptom.
Background technology
Depression complicated mechanism, clinical syndrome is various, and course of disease length, easily recurrence.Depression betide world community,
In the crowd of all orders of society and various cultural context.With social development, the increasing of stressor, sickness rate is also in increase year by year
Trend.World Health Organization (WHO) (WHO) predicts, the disease that will become developing country's most serious to the year two thousand twenty depression is born
Carry on a shoulder pole, severe depression can become dead and disabled second largest reason when the time comes.
During what huge life and work pressure led to mostly be, major depressive disorder, simple psychotherapy can not reach ideal
Clinical efficacy.Therefore clinical in addition to giving the necessary comfort of patient, dredging, instruct, rely primarily on medicine to control, main medicine
Thing includes tricyclic antidepressant, tetracyclic antidepressants etc..Existing medicine antidepressant spectrum is narrow, toxic and side effects are big, have addiction
Property and the defect such as contraindication, severely impacted treatment and the compliance of clinic.Chinese medicine few side effects are in Western medicine, but curative effect is delayed
Slowly.And the traditional Chinese medical science controls standard for the objective complete typing opinion generally acknowledged of diagnosis and treatment still neither one of depression, how
Systematic difference traditional Chinese medical herbal treatment depression need to study further.
Therefore, searching can effectively prevent or treat depression, reduce depressive symptom, and safety does not have any toxic and side effects
Medicine be clinical in the urgent need to.The present inventor finds through research, and Bacillus coagulans can effectively be prevented or be treated suppression
Strongly fragrant disease, does not have safely any toxic and side effects, and effect is better than bacillus bifiduss, and has no that correlational study is reported, this invention of special application is specially
Profit.
Content of the invention
It is an object of the invention to provide a kind of preparation that can prevent or treat depression, said preparation is by Bacillus coagulans system
Become.
The preparation of the preparation of the present invention is implemented preferably through following step, but is not limited to this preparation technology, known
The preparation technology enabling all permissible：Take the sample that may contain Bacillus coagulans, then sample be placed in sterilizing bottle,
Therefrom take a certain amount of sample to add in the diluent of 18mL sterilizing during research, fully mix, in aseptic operating platform, carry out
10-1、10-2、10-3、10-4、10-5、10-6、10-7Gradient dilution, takes 10-5、10-6、10-7Three dilution gradients, are respectively coated in solidifying
On knot bacillus cereuss selectivity single bacterium colony separation solid medium, it is placed in incubator, cultivates 48 hours at 37 DEG C, select growing way good
Good single bacterium colony is inoculated in liquid amplification culture medium respectively, is placed in incubator, amplification cultivation 48 hours at 37 DEG C.By gained
After medium centrifugal (12000rpm) isolates thalline, by thalline lyophilisation, modulate and mycopowder is dried, then basis
《The outstanding Bacteria Identification handbook of uncle》, Related Bacteria identification document or 16S rRNA sequence comparative analysis carry out Bacillus coagulans identification
And toxicity test, avirulent Bacillus coagulans are dried mycopowder desired proportions interpolation adjuvant and make tablet, capsule, dissipate
The various dosage form such as agent, powder or liquid preparation, also can add the oligosaccharide such as other viable bacterias or oligofructose to play synergism.
Bacillus coagulans selectivity single bacterium colony separation solid medium is preferably but not limited to：Purified water 1000mL, egg
White peptone 10g, beef leaches thing 10g, dibasic ammonium citrate 2g, sodium acetate 5g, yeast powder 5g, glucose 5g, potassium dihydrogen phosphate 2g, tells
Warm 80 1.0ml, Calcium Carbonate 20g, magnesium sulfate 0.58g, manganese sulfate 0.25g, agar 15g, adjust pH 6.2-6.5,115 DEG C of high pressure go out
Bacterium 20min.
Bacillus coagulans liquid amplification culture medium is preferably but not limited to：Purified water 1000mL, peptone 10g, beef
Leaching thing 3g, sodium chloride 5g, glucose 5g, adjust pH7,115 DEG C of autoclaving 20min.
For being further elaborated with the present invention, inventor utilizes said method to pass through Bacillus coagulans selectivity single bacterium colony
Separate solid medium isolation identification and gone out avirulent Bacillus coagulans, Bacillus coagulans of the present invention are not limited to
In bacterium described to illustrate the invention, as long as avirulent Bacillus coagulans are all of the present invention, all in the guarantor of the present invention
In the range of shield.
Bacillus coagulans of the present invention are preferably but not limited to Bacillus coagulans TBC169 deposit number CGMCC1207
Or Bacillus coagulans deposit number CGMCC1.2407.
The bacteriological quality of the Bacillus coagulans that the present invention preferably uses in implementing to illustrate：
1st, to illustrate the invention, the present invention utilizes the detached Bacillus coagulans of said method is Bacillus coagulans
TBC169 deposit number CGMCC1207.
2nd, colonial morphology
Micro- sem observation：Shaft-like, Gram-positive.
Plate morphology：Bacterium colony is white, circular, neat in edge, size 2-3mm.
3rd, Physiology and biochemistry identification
Gelatin liquefaction：-；Catalase：+；VP tests：+；Phenylalanine deaminase test-.
4th, glycolysiss experimental identification
Glucose：+；Maltose：+；Sucrose：+；Xylose：-；Fructose：+；Rhamnose：-；Lactose：+；Inulin：+；Gala
Sugar：+；Dextrin：+.
5th, detached bacterium carries out 16S rRNA gene sequencing, records in sequence BLAST and GenBank and RDP data base
Gene order carry out similarity analysis, determine detached bacterium be Bacillus coagulans.
Bacillus coagulans of the present invention refer to the bion of work.
The present invention be using effective dose as stated above detached Bacillus coagulans as main active ingredient, according to one
Fixed preparation process, add conventional excipient, flavoring agent, disintegrating agent, preservative, lubricant, wetting agent, adhesive, solvent,
The adjuvants such as thickening agent, solubilizing agent, make any fit for service dosage form, such as tablet, capsule, granule, powder, liquid
The dosage forms such as body preparation, powder.
Bacillus coagulans of the present invention make active bacteria formulation as key agents active ingredient.
Indication effective dose of the present invention refer to as stated above detached Bacillus coagulans according to described above individually or
Combine the total viable count comprising as the solid live bacteria preparation that key agents active ingredient is made and cannot be below 1 × 106CFU/g,
Typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g.
Indication effective dose of the present invention refer to as stated above detached Bacillus coagulans according to described above individually or
Combine the total viable count comprising as the liquid active bacteria formulation that key agents active ingredient is made and cannot be below 1 × 106CFU/mL,
Typically 1 × 107More than CFU/mL, can reach 1 × 1012CFU/mL or 1 × 1012More than CFU/mL.
Preparation of the present invention include Bacillus coagulans be used alone or with other drugs use in conjunction, especially include coagulating
Knot bacillus cereuss be used alone or with bacillus bifiduss use in conjunction.
Bacillus bifiduss of the present invention refer to the bion of work.
In the preparation of bacillus bifiduss use in conjunction of the present invention, the total viable count of bacillus bifiduss that solid preparation comprises is not low
In 1 × 106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or
The total viable count of bacillus bifiduss that liquid preparation comprises is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, highest can
Reach 1 × 1012CFU/mL or 1 × 1012More than CFU/mL.
Due to present invention firstly discloses Bacillus coagulans make preparation in prevention or treatment as main active ingredient
Application in depression, the preparation therefore containing above-mentioned Bacillus coagulans is preventing or is treating the application in depression preparation all to belong to
In protection scope of the present invention.
Bacillus coagulans of the present invention, when making any dosage form, are respectively provided with prevention or treat depression
Effect.If being prepared into preparation containing Bacillus coagulans composition in its component, in its packaging or the mark such as description or
As long as indicating on other any propaganda materials or prompting having prevention or the effect for the treatment of depression, then fall into the protection of the present invention
Within the scope of.
Bacillus coagulans of the present invention can make medicine, health food, food or beverage etc..
Specific embodiment
Preparation example explanation：The above-mentioned preparation to Bacillus coagulans preparation illustrates, here by condensation spore
Bacillus TBC169 deposit number CGMCC1207 or Bacillus coagulans deposit number CGMCC1.2407 (Bacillus coagulans preservation
Numbering CGMCC1.2407 be purchased from China Committee for Culture Collection of Microorganisms's common micro-organisms center) as a example carry out specifically
Bright, preparation method those skilled in the art of other Bacillus coagulans strain preparations are easy to grasp by the present embodiment, its
Preparation method those skilled in the art of his dosage form are easy to grasp by this enforcement, and here no longer describes explanation one by one.Preparation
Method is not limited to described in the embodiment of the present invention, known can reach preparation purpose method all permissible, the system of embodiment
Standby explanation is the description of the invention, is not limiting the scope of the invention.
The preparation of preparation embodiment 1 Bacillus coagulans powder
The preparation of 1 mycopowder and the identification of strain
Take the samples such as the feces of people, soil, haystack substrate, then sample is placed in sterilizing bottle, therefrom takes 2 grams of samples
Add in the diluent of 18mL sterilizing, fully mix, in aseptic operating platform, carry out 10-1、10-2、10-3、10-4, 10-5, 10-6,
10-7Gradient dilution, takes 10-5, 10-6, 10-7Three dilution gradients, coat Bacillus coagulans selectivity single bacterium colony separation solid
In culture medium, it is placed in incubator, cultivates 48 hours at 37 DEG C, select the single bacterium colony growing fine to be inoculated into Bacillus coagulans liquid
In body amplification culture medium, amplification cultivation 48 hours at 37 DEG C.Gained medium centrifugal (12000rpm) is isolated after thalline, will
Thalline lyophilisation, modulates and mycopowder is dried, and viable count is 1 × 109More than CFU/g, then carries out strain identification, warp
Physiology and biochemistry and 16S rRNA sequence comparative analysis are accredited as Bacillus coagulans, are Bacillus coagulans TBC169 deposit number
CGMCC1207.
Prepared by Bacillus coagulans deposit number CGMCC1.2407 mycopowder, by Bacillus coagulans deposit number
CGMCC1.2407 is inoculated in Bacillus coagulans liquid amplification culture medium, amplification cultivation 48 hours at 37 DEG C.Gained is cultivated
After liquid centrifugation (12000rpm) isolates thalline, thalline lyophilisation modulating and mycopowder is dried, viable count is 1 ×
109More than CFU/g.
2 toxicity tests
2.1 animals and packet take 30 SPF rank mices, 6-8 week old, body weight 14-18g, random segregation junction bacillus cereuss
CGMCC1207 group, 1.2407 groups of Bacillus coagulans CGMCC and non-administered group, every group 10.
Above-mentioned different Bacillus coagulans mycopowder is modulated to be 1 containing bacterium number by 2.2 preparation bacterium solution respectively with purified water
×109The bacterium solution of CFU/mL.
2.3 methods each Bacillus coagulans group and non-administered group all give identical normal feedstuff, and rearing conditions are homogeneous
Cause, each Bacillus coagulans group gavages Bacillus coagulans bacterium solution 0.5mL daily, and non-administered group gavages purified water 0.5mL daily,
Feeding 14 days, observes body weight and toxic reaction.
2.4 result
All abnormal conditions in each group mice, does not occur chatter, spasm, movement disorder, attitude abnormal, no eyeball is dashed forward
Go out, urinate normal, skin, breathing are normal, no death condition has no toxic reaction.
3 are prepared into the dosage forms such as powder
After above-mentioned steps and method isolation identification, through experimental check avirulence so that it may by Bacillus coagulans strain
Make mycopowder, then according to needing interpolation relevant auxiliary materials to make various dosage forms, preferably according to the viable count of Bacillus coagulans mycopowder,
Add starch in proportion and make powder, make viable count be not less than 1 × 107CFU/g, then packs.
Application effect embodiment explanation：
The present invention is with Bacillus coagulans TBC169 deposit number CGMCC1207 or Bacillus coagulans deposit number
CGMCC1.2407 is the application effect that representative illustrates Bacillus coagulans.Used in the present invention, bacillus bifiduss come from market
Sell product, the bifidobacteria viable bacteria that the public can buy.
Application effect embodiment 1：Application in treatment depression for the Bacillus coagulans
1 model group preparation：
1.1 laboratory animals choose adult male SD rats (body weight 200-220g, purchased from dimension tonneau China Experimental Animal Center),
Experiment prospective adaptation is raised one week：Natural lighting, 22 ± 2 DEG C of room temperature, freely absorb food and water, feedstuff is changed in daily timing, leads to
Wind is good, exclusion other stressors interference.
1.2 preparation methods adopt chronic not it is contemplated that gently stress processing method, for above-mentioned adaptation raise experiment move
Thing takes following 10 kinds of Coping styles to be processed：Fasting 24h, taboo water 24h, folder tail (at rat root of the tail portion 1cm) 5min, daytime
Night overturns 24h, 4 DEG C of cold-wate swimming 5min, 45 DEG C of environment 5min, moist bedding and padding 24h, 45 degree of 24h of inclination, behavior constraint 4h, water
Horizontal tremble swings 60 times/min 45min.Above-mentioned 10 kinds method stress carry out random process in 28 days, take a kind of method, phase daily
Same stimulation can not continuously occur and at least be spaced more than 7 days, set up Depression in Rats model.
2 Drug therapy experiments：
The method that 2.1 experimental techniques press 1.1 adapts to raise adult male SD rats one week, and rat is randomly divided into 6 groups of (n
=10)：1207 groups of Bacillus coagulans CGMCC, 1.2407 groups of Bacillus coagulans CGMCC, bacillus bifiduss group, Prozac group,
Model control group, Normal group.Each treatment group and matched group all give identical normal feedstuff, and rearing conditions are all consistent,
Each Bacillus coagulans group and the use of bacillus bifiduss group are 1 × 10 containing bacterium number6CFU/mL (modulates mycopowder with 0.9% normal saline)
Bacterium solution gavage 0.5mL, Prozac group (is modulated to the medicine of 0.2mg/mL using the medicinal liquid of 0.2g/kg with 0.9% normal saline
Liquid) gavage 0.5mL, matched group group gavages 0.9% normal saline 0.5mL daily.Should using stating chronic Unpredictability described in 1.2
Sharp method sets up rat chronic Stress Depression Model, and carries out a pharmaceutical intervention before each modeling, and it is right that comparative drug is intervened
Behavioristicss' change of the gentle Stress model rat of chronic not predictability.
2.2 pharmaceutical intervention are to chronic not it is contemplated that measuring respectively before and after the Behavior evaluation experiment of gentle Stress model rat
The body weight of rat, experiment carries out Behavior evaluation after terminating, including spacious field experiment, forced swim test and sucrose solution preference experiment.
Data carries out statistical analysis using SPSS 21.0.
3 results
3.1 pharmaceutical intervention chronic not it is contemplated that after gentle Stress model rat body weight change
After Bacillus coagulans CGMCC 1207 is intervened, rat body weight is 389.87 ± 11.68g, after CGMCC1.2407 intervenes
Rat body weight is 381.59 ± 11.12g, no significant difference (P ＞ 0.05) between the two, with Prozac group (376.11 ±
Also no significant difference (P ＞ 0.05) between 21.97g), extremely significantly raises (P ＜ compared with model group (305.33 ± 16.89g)
0.01).After Bacillus coagulans CGMCC 1207 and CGMCC1.2407 intervention, rat body weight is all remarkably higher than bacillus bifiduss group
(358.94 ± 14.11g) (P ＜ 0.05).Bacillus coagulans to rat chronic not it is contemplated that gently stress body weight afterwards increase
There is significant curative effect, its body weight evolution is higher than Prozac group, and is significantly higher than bacillus bifiduss group.It is shown in Table 1.
Table 1 pharmaceutical intervention chronic not it is contemplated that after Stress model rat body weight change statistical analysiss
| Packet | Number of cases (n) | Body weight (g) |
| 1207 groups of Bacillus coagulans CGMCC | 10 | 389.87±11.68 |
| 1.2407 groups of Bacillus coagulans CGMCC | 10 | 381.59±11.12 |
| Bacillus bifiduss group | 10 | 358.94±14.11 |
| Prozac group | 10 | 376.11±21.97 |
| Model control group | 10 | 305.33±16.89 |
| Normal group | 10 | 421.76±13.62 |
3.2 pharmaceutical intervention chronic not it is contemplated that after gentle Stress model rat behavioristicss' change
Bacillus coagulans CGMCC 1207 and CGMCC1.2407 intervene after the spacious field traversing times of rat, upright number of times,
Reason hair number of times all pole compared with model group significantly improves (P ＜ 0.01), and the forced swimming dead time all extremely significantly shortens (P ＜
0.01), sucrose solution Preference all pole significantly improves (P ＜ 0.01), between the two no significant difference (P ＞ 0.05), and and fluoxetine
No significant difference (P ＞ 0.05) between treatment group；Bacillus coagulans CGMCC 1207 and CGMCC1.2407 and bacillus bifiduss phase
After intervention, the spacious field traversing times of rat, upright number of times, reason hair number of times are significantly increased (P ＜ 0.05) ratio, and forced swimming is motionless
Time all significantly shortens (P ＜ 0.05), and sucrose solution Preference is significantly increased (P ＜ 0.05).Rat chronic is not it is contemplated that gently should
After swashing, Bacillus coagulans intervention can substantially reduce the Depressive behavior of rat, and its effect is significant is better than bacillus bifiduss, with fluoxetine
Between no significant difference.It is shown in Table 2.
Table 2 pharmaceutical intervention chronic not it is contemplated that after Stress model rat behavior change statistical analysiss
4 discussion
Chronic not it is contemplated that the body weight that gentle Stress model group compares rat with Normal group substantially reduces, and medicine is done
Organize in advance and compare the body weight of rat with model group and all substantially rise, wherein the curative effect of Bacillus coagulans group is all considerably better than bifid bar
Bacterium group, and it is better than Prozac group.Show that depression can lead to organism metabolic disorder thus leading to weight loss, Bacillus coagulans are done
The body weight that rat reduces because depressed can significantly be recovered in advance.Bonding behavior assessment result shows, after Bacillus coagulans are intervened,
It is chronic that not it is contemplated that the Depressive behavior that gently stress occur is significantly improved, its effect is substantially better than bacillus bifiduss group,
And intervene retarded depression symptom improvement no significant difference with Prozac group.Show that Bacillus coagulans can reach as main active
To the antidepressant effect consistent with fluoxetine effect, thus providing new solution for the treatment and prevention of depression.
Bacillus coagulans preparation can effectively prevent or treat depression hence it is evident that reducing depressive symptom, and no any poison
Side effect, application compliance is good, is to prevent or treat the new method of depression, new breakthrough.
Microorganism fungus kind used in implementation process for the present invention is in August in 2004 23 days in Chinese microorganism strain
Preservation administration committee common micro-organisms center (Datun Road, Chaoyang District, Beijing City, Institute of Microorganism, Academia Sinica's postcode
100101) preservation.Classification And Nomenclature：Bacillus coagulans Bacillus coagulans, deposit number 1207.Bacillus coagulans
TBC169 deposit number CGMCC1207 is voluntarily separated by the present patent application unit and obtains, and sells in commercial channel, and
Granted patent protects (patent No. 200410098660.4), and according to the regulation of Guidelines for Patent Examination, the public can be from commercial channel
Buy or authorized, without preservation, proved, therefore, the present invention does not provide Bacillus coagulans without offer preservation
TBC169 deposit number CGMCC1207 preservation proves.
Bacillus coagulans CGMCC 1.2407 is purchased from China Committee for Culture Collection of Microorganisms's common micro-organismss
The heart.
Claims (10)
1. application in preparation prevention or treatment depression preparation for the Bacillus coagulans.
2. as described in claim 1 application it is characterised in that described preparation include Bacillus coagulans be used alone or and other
Drug combination.
3. apply it is characterised in that described preparation includes medicine, health food, food, beverage as described in claim 1.
4. apply as described in claim 1 it is characterised in that described Bacillus coagulans refer to the bion of work.
5. apply as described in claim 1 it is characterised in that described Bacillus coagulans include Bacillus coagulans TBC169 guarantor
Hide numbering CGMCC1207 or Bacillus coagulans deposit number CGMCC1.2407.
6. as described in claim 2 application it is characterised in that described preparation includes Bacillus coagulans is used alone or and bifid
Bacillus use in conjunction.
7. apply as described in claim 6 it is characterised in that described bacillus bifiduss refer to the bion of work.
8. as described in claim 1, application, it is characterised in that prevention or treatment depression, reduces depressive symptom.
9. as described in claim 1 preparation it is characterised in that the total viable count of Bacillus coagulans that solid preparation comprises is not less than 1
×106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or liquid
The total viable count of Bacillus coagulans that body preparation comprises is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, highest
Can reach 1 × 1012CFU/mL or 1 × 1012More than CFU/mL.
10. as described in claim 6 preparation it is characterised in that the total viable count of bacillus bifiduss that solid preparation comprises be not less than 1 ×
106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or liquid
The total viable count of bacillus bifiduss that preparation comprises is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, can reach
1×1012CFU/mL or 1 × 1012More than CFU/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611060368.2A CN106474162A (en) | 2016-11-28 | 2016-11-28 | Application in preparation prevention or treatment depression preparation for the Bacillus coagulans |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611060368.2A CN106474162A (en) | 2016-11-28 | 2016-11-28 | Application in preparation prevention or treatment depression preparation for the Bacillus coagulans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106474162A true CN106474162A (en) | 2017-03-08 |
Family
ID=58275251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611060368.2A Withdrawn CN106474162A (en) | 2016-11-28 | 2016-11-28 | Application in preparation prevention or treatment depression preparation for the Bacillus coagulans |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106474162A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107115362A (en) * | 2017-04-28 | 2017-09-01 | 青岛东海药业有限公司 | Application of the bacillus coagulans in prevention or treatment bronchial astehma preparation is prepared |
| CN107115363A (en) * | 2017-06-05 | 2017-09-01 | 青岛东海药业有限公司 | Application of the bacillus coagulans in prevention or treatment chronic fatigue syndrome preparation is prepared |
| CN113181342A (en) * | 2021-05-19 | 2021-07-30 | 天津市宝恒生物科技有限公司 | Bacillus coagulans preparation for treating depression |
| CN116850213A (en) * | 2023-07-24 | 2023-10-10 | 青岛东海药业有限公司 | Probiotic composition for improving maternal and offspring autism depression behavior and application thereof |
| CN117965398A (en) * | 2024-03-29 | 2024-05-03 | 微康益生菌(苏州)股份有限公司 | Composite probiotics with mood stabilization effect and application thereof |
| CN117965398B (en) * | 2024-03-29 | 2024-06-07 | 微康益生菌(苏州)股份有限公司 | Composite probiotics with mood stabilization effect and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070071739A1 (en) * | 2005-09-27 | 2007-03-29 | Cobb Mark L | Treatment of bipolar disorder utilizing anti-fungal compositions |
| CN101926831A (en) * | 2006-06-26 | 2010-12-29 | 青岛东海药业有限公司 | Application of Bacillus coagulans to preparing composite preparations for preventing and treating shit odor and shit odor poisoning syndrome |
-
2016
- 2016-11-28 CN CN201611060368.2A patent/CN106474162A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070071739A1 (en) * | 2005-09-27 | 2007-03-29 | Cobb Mark L | Treatment of bipolar disorder utilizing anti-fungal compositions |
| CN101926831A (en) * | 2006-06-26 | 2010-12-29 | 青岛东海药业有限公司 | Application of Bacillus coagulans to preparing composite preparations for preventing and treating shit odor and shit odor poisoning syndrome |
Non-Patent Citations (1)
| Title |
|---|
| MASSACHUSETTS GENERAL HOSPITAL NEWS RELEASE: "Probiotics under study as treatment for IBS and depression", 《HTTPS://WWW.MASSGENERAL.ORG/NEWS/PRESSRELEASE.ASPX?ID=1307》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107115362A (en) * | 2017-04-28 | 2017-09-01 | 青岛东海药业有限公司 | Application of the bacillus coagulans in prevention or treatment bronchial astehma preparation is prepared |
| CN107115363A (en) * | 2017-06-05 | 2017-09-01 | 青岛东海药业有限公司 | Application of the bacillus coagulans in prevention or treatment chronic fatigue syndrome preparation is prepared |
| CN113181342A (en) * | 2021-05-19 | 2021-07-30 | 天津市宝恒生物科技有限公司 | Bacillus coagulans preparation for treating depression |
| CN113181342B (en) * | 2021-05-19 | 2022-11-08 | 天津市宝恒生物科技有限公司 | Depression treating bacillus coagulans preparation |
| CN116850213A (en) * | 2023-07-24 | 2023-10-10 | 青岛东海药业有限公司 | Probiotic composition for improving maternal and offspring autism depression behavior and application thereof |
| CN116850213B (en) * | 2023-07-24 | 2024-04-30 | 青岛东海药业有限公司 | Probiotic composition and application thereof |
| CN117965398A (en) * | 2024-03-29 | 2024-05-03 | 微康益生菌(苏州)股份有限公司 | Composite probiotics with mood stabilization effect and application thereof |
| CN117965398B (en) * | 2024-03-29 | 2024-06-07 | 微康益生菌(苏州)股份有限公司 | Composite probiotics with mood stabilization effect and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106389479A (en) | Application of bacillus coagulans in preparing preparation for preventing or treating autism | |
| CN107616985A (en) | Bacillus coagulans preparation and its application | |
| CN106474162A (en) | Application in preparation prevention or treatment depression preparation for the Bacillus coagulans | |
| CN103565848B (en) | Application of bacillus coagulans in preparing preparations for preventing and treating helicobacter pylori infection | |
| CN101559095B (en) | Veterinary compound acanthopanax granules with immunopotentiation and preparation method thereof | |
| WO2018090983A9 (en) | Saponin compound for improving intestinal microflora, preparation method and use thereof | |
| CN104415061B (en) | Edible composition and its production and use | |
| CN107854495A (en) | Bacillus coagulans is preparing the application in reducing blood urine acid supplement | |
| CN106420840A (en) | Application of Clostridium butyricum in preparation of preparations for preventing or treating depression | |
| CN112852670B (en) | Bifidobacterium infantis DH231 and fermentation product, application and microecological preparation thereof | |
| CN105624069A (en) | Lactobacillus rhamnosus preparation and application thereof | |
| CN1735431B (en) | Whole bacterial cells as immune modulator | |
| KR100918628B1 (en) | Composition for prevention or treatment of liver toxicity comprising fungus-fermented Ssangwhatang | |
| CN111329982B (en) | Novel application of bupleurum tenue granules in combination with chloroquine phosphate | |
| CN109090229A (en) | A kind of citrus composite preservative and preparation method thereof | |
| CN106361777A (en) | Application of clostridium butyricum in preparation of preparation for preventing or treating autism | |
| CN107115363A (en) | Application of the bacillus coagulans in prevention or treatment chronic fatigue syndrome preparation is prepared | |
| CN110090231A (en) | Application of the clostridium butyricum in preparation prevention or treatment cholangiocarcinoma preparation | |
| CN104997812B (en) | The drug and its preparation method and application of anti-cerebral ischemia reperfusion injury | |
| CN1094762C (en) | Fresh rehmannia root extract for proliferation of bifidobactor and extraction method thereof | |
| CN113181131A (en) | Novel drug formula for immunotherapy and tablet structure thereof | |
| CN106890196A (en) | Application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared | |
| CN107115362A (en) | Application of the bacillus coagulans in prevention or treatment bronchial astehma preparation is prepared | |
| CN107080755A (en) | Application of the bacillus coagulans in prevention or treatment COPD preparation is prepared | |
| CN106822186A (en) | Application of the bacillus coagulans in prevention or treatment Parkinson's preparation is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170308 |